Top Story Today
Medicare's Coverage Lag for Breakthrough Devices? The FDA Wants It Gone in 60 Days.
Getting FDA approval for a life-saving device, then waiting a year or more for Medicare to cover it, has been one of medtech's cruelest bottlenecks. A new inter-agency program called RAPID embeds CMS into clinical trial design from the start, so that on the same day the FDA grants approval, CMS can issue a proposed coverage determination. The target: full Medicare coverage within 60 to 90 days of approval instead of the typical year-plus timeline. About 40 devices already qualify, with no annual cap, a massive upgrade over the previous pathway's limit of five per year.
Why it matters: If RAPID delivers on its promise, medtech companies get a dramatically shorter path to revenue, investors get less reimbursement uncertainty to price in, and patients stop waiting for devices their doctors already want to prescribe.
Read more →Clinical and Regulatory
Roche's Oral MS Pill Matches Its Own Blockbuster Infusion, but a Death Imbalance Looms
Roche's fenebrutinib, an oral pill that crosses the blood-brain barrier, cut MS relapses by up to 59% and matched its blockbuster infusion Ocrevus in progressive disease. The catch: seven deaths on fenebrutinib versus one on comparator in the relapsing trials during the 96-week reporting period. Roche plans to file in the first half of 2026, essentially betting against its own $5.9 billion product before patent expiration forces the issue.
Read more →The FDA Wants to Let Compounding Pharmacies Make 14 Restricted Peptides Again
HHS Secretary Kennedy announced plans to reclassify roughly 14 peptides (including BPC-157 and TB-500) from "do not touch" to compounding-eligible, arguing the restrictions just pushed patients to the black market. An advisory committee meets in July 2026 to review the first batch. These aren't GLP-1 drugs, but the move strengthens the same pharmacy infrastructure competing with Big Pharma on price.
Read more →Revolution Medicines Brings a Full KRAS Arsenal to AACR 2026
For 40 years, KRAS was oncology's "undruggable" target. Revolution Medicines showed up at AACR with clinical data across multiple drugs and tumor types. Lead candidate daraxonrasib hit a 47% response rate in untreated pancreatic cancer (58% with chemo), while mutation-selective zoldonrasib posted a 52% response in lung cancer. The stock has surged over the past year.
Read more →AI and Drug Discovery
Roche Deploys 3,500 NVIDIA GPUs to Build Pharma's Largest AI Operation
Roche now runs over 3,500 GPUs dedicated to drug discovery, manufacturing, and diagnostics; the biggest AI computing setup in pharma. The partnership with NVIDIA embeds AI across the entire R&D process, from protein modeling to digital twins of factories. Eli Lilly is running a parallel arms race with its own billion-dollar NVIDIA lab. Jensen Huang sells the shovels to both sides.
Read more →Funding and Financings
Generate Biomedicines Raises $400M in Biggest AI Biotech IPO Since 2024
Generate Biomedicines priced 25 million shares at $16 each, raising $400 million on a $2.2 billion valuation. The Flagship Pioneering-backed company uses generative AI to design proteins from scratch, with a Phase 3 asthma drug leading the pipeline. The IPO is the highest-profile test yet of whether AI-designed drugs can hold up in public markets.
Read more →Avalyn Pharma Targets $200M IPO for Inhaled Lung Disease Therapies
Avalyn wants to take existing oral IPF drugs, reformulate them for inhalation, and deliver them straight to damaged lung tissue. The pitch is elegant, but early Phase 2b data showed good tolerability without a strong signal on the key efficacy measure. Shares are expected to begin trading the week of April 27, adding to a 2026 IPO market that already hit $2.2 billion in Q1.
Read more →